NMDA-antagonistsOpioid-antagonistsPaintreatmentReviews-on-treatmentThe potential beneficial effect of coadministration of opiates with antagonists of the N-methyl-D-aspartate (NMDA) receptor for glutamate are discussed. There is a growing body of experimental data indicating that selective NMDA antagonists ...
Monoamine oxidase inhibitors (MAOIs), N-methyl D-aspartate (NMDA) antagonists and neuroactive steroid gamma-aminobutyric acid (GABA)-A receptor positive modulators, tend to be less widely prescribed as they come with lifestyle modifications. MAOIs interact poorly with foods like cheese, wine and h...
in unipolar depression and bipolar disorder. Controlled clinical studies have shown that several NMDA receptor antagonists can quickly (within a few hours) and effectively relieve severe, chronic and refractory depression, such as ketamine, rapastinel, scopolamine, etc. NMDA receptor antagonists are also...
It was hypothesized that GABAB antagonists might reverse this effect by reducing glutamatergic excitotoxicity via indirect effects on NMDA receptors. Preclinical studies in rats, mice, and rhesus monkeys were positive. In the first phase II trial (n = 110) in MCI, SGS742 was well tolerated at ...
In contrast, although published clinical studies to date have suggested modest antidepressant efficacy of some alterna- tive NMDA receptor antagonists, thus far these drugs lack the robust rapid or sustained efficacy of ketamine, and in some cases (eg, memantine) they have been proven clinically ...
The coanalgesic drug group include gabapentinoids (gabapentin, pregabalin), antidepressants (TCAs, duloxetine, and venlafaxine), corticosteroids, bisphosphonates, NMDA antagonists, and cannabinoids.9,92,107,108 Although it is criti- cized frequently, the most common approac...
Targeting the NMDA receptor with specific antagonists could, in addition to having direct effects on nociceptive transmission in nerves, affect the NMDA receptor on mast cells and thereby hinder the degranulation-dependent release of sensitizing substances [50, 51]. However, further studies are required...
This hypothesis is, for many clinicians, the rationale for postponing and sparing L-DOPA and to begin therapy with dopamine agonists, monoamine oxidase type B (MAO-B) inhibitors, or N-Methyl-D-aspartate (NMDA) antagonists. Furthermore, clinical studies have demonstrated that early treatment with...
’ As a result, researchers are now testing orexin antagonists like suvorexant in clinical trials as anti-craving and addiction treatments, and against binge eating, but not obesity. ‘The challenge is that people with obesity are not necessarily binge eaters,’ says Borgland. ‘There’s a lo...
Animal and human studies suggest NMDA antagonists worsen executive function. This dysfunction is often caused by glutamate toxicity. And if this persists, you end up with diseases like schizophrenia. This double-blind, placebo-controlled study worked with 75 adults with schizophrenia. They were stable...